Orlistat, a novel potent antitumor agent for ovarian cancer: proteomic analysis of ovarian cancer cells treated with Orlistat

International Journal of Oncology
Hui-Qiong HuangXia Zhao

Abstract

Orlistat is an orally administered anti-obesity drug that has shown significant antitumor activity in a variety of tumor cells. To identify the proteins involved in its antitumor activity, we employed a proteomic approach to reveal protein expression changes in the human ovarian cancer cell line SKOV3, following Orlistat treatment. Protein expression profiles were analyzed by 2-dimensional polyacrylamide gel electrophoresis (2-DE) and protein identification was performed on a MALDI-Q-TOF MS/MS instrument. More than 110 differentially expressed proteins were visualized by 2-DE and Coomassie brilliant blue staining. Furthermore, 71 proteins differentially expressed proteins were positively identified via mass spectrometry (MS)/MS analysis. In particular, PKM1/2, a key enzyme involved in tumorigenesis, was found to be significantly downregulated in SKOV3 cells following treatment with Orlistat. Moreover, PKM1/2 was proved to be downregulated in SKOV3 cells by western blot analysis after treatment with Orlistat. Taken together, using proteomic tools, we identified several differentially expressed proteins that underwent Orlistat-induced apoptosis, particularly PKM2. These changes confirmed our hypothesis that Orlistat is a potentia...Continue Reading

References

Jul 5, 1994·Proceedings of the National Academy of Sciences of the United States of America·F P KuhajdaG R Pasternack
Jan 1, 1997·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·E S PizerF P Kuhajda
May 17, 2000·The Journal of Experimental Medicine·J JankeS Scherneck
Oct 18, 2000·Oncology Reports·P L AlòU Di Tondo
Sep 27, 2002·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·T NemotoM Gotoh
May 13, 2004·The Journal of Biological Chemistry·Lynn M KnowlesJeffrey W Smith
Feb 25, 2005·Lipids·Subrahmanyam S Chirala, Salih J Wakil
May 24, 2005·Seminars in Cancer Biology·Sybille MazurekErich Eigenbrodt
Jul 6, 2005·Biochemistry·Jill D DombrauckasAndrew D Mesecar
Mar 3, 2006·Molecular and Cellular Biochemistry·Leslie C Costello, Renty B Franklin
May 3, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mari RakiAkseli Hemminki
Mar 22, 2007·The Journal of Biological Chemistry·Andrzej WitkowskiStuart Smith
Jul 10, 2007·Nature Structural & Molecular Biology·Charles W PembleW Todd Lowther
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Apr 22, 2008·International Journal of Cancer. Journal International Du Cancer·Gilles A SpodenWerner Zwerschke
Jun 12, 2010·Expert Review of Proteomics·Rui LiuCanhua Huang

❮ Previous
Next ❯

Citations

Apr 5, 2014·Journal of Pharmaceutical and Biomedical Analysis·Miguel Angel Merlos RodrigoRene Kizek
Mar 24, 2018·International Journal of Cancer. Journal International Du Cancer·Efthymia PapaevangelouYuen-Li Chung
May 4, 2018·Expert Opinion on Investigational Drugs·Alejandro Schcolnik-CabreraAlfonso Dueñas-González

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis